- Home
- IPHA vs HCAT Comparison
IPHA vs HCAT Comparison
Compare IPHA & HCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | HCAT |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 152.1M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | IPHA | HCAT |
|---|---|---|
| Price | $1.71 | $2.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $5.00 | $4.25 |
| AVG Volume (30 Days) | 18.3K | ★ 661.8K |
| Earning Date | 03-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,839,695.00 | ★ $316,063,000.00 |
| Revenue This Year | $22.29 | $3.30 |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.63 |
| 52 Week Low | $1.63 | $2.02 |
| 52 Week High | $2.63 | $5.89 |
Technical Indicators
Market Signals| Indicator | IPHA | HCAT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 41.00 |
| Support Level | N/A | $2.08 |
| Resistance Level | N/A | $2.37 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 13.70 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About HCAT Health Catalyst Inc
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.